Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 4, 2009
Business Overview: IRIDEX is a worldwide provider of therapeutic-based laser systems, consumable probes, and delivery devices for ophthalmology and aesthetics. The company operates in two reportable segments: Ophthalmology and Aesthetics. It sells products directly in the U.S. and through approximately 100 independent distributors in 107 countries.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended July 4, 2009 |
Six Months Ended July 4, 2009 |
|---|---|---|
| Revenues | $10,513 | $21,249 |
| Gross Profit | $4,829 | $9,877 |
| Gross Margin | 45.9% | 46.5% |
| Operating Income | $399 | $762 |
| Net Income | $1,198 | $1,422 |
| Diluted EPS | $0.13 | $0.16 |
| Cash and Equivalents | $6,618 | $6,618 |
| Working Capital | $11,328 | $11,328 |
| Bank Line of Credit Outstanding | $4,478 | $4,478 |
Note: Net income includes a one-time legal settlement gain of $800,000 received in the quarter.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 18.6% ($2.4M) for the three months and 12.9% ($3.1M) for the six months compared to the prior year periods.
- Aesthetics Segment: Experienced a significant decline of 39.8% (three months) and 30.3% (six months), driven by the global economic slowdown and reduced demand for elective procedures.
- Ophthalmology Segment: Declined modestly by 6.4% (three months) and 3.3% (six months), primarily due to reduced capital equipment spending in the U.S. market.
- Profitability Improvement: Despite lower revenues, the company returned to profitability. Operating income improved from a loss of $256,000 to income of $399,000 for the three-month period.
- Gross Margin Expansion: Gross margin improved to 45.9% (from 41.3% prior year) due to the cessation of intangible asset amortization in cost of revenues, a favorable product mix shift toward higher-margin ophthalmology products, and reduced inventory reserves.
- Expense Reduction: Operating expenses decreased significantly. General and Administrative expenses dropped 31.8% and Sales and Marketing expenses dropped 17.0% year-over-year, attributed to headcount reductions and lower commissions.
- Cash Flow: Net cash provided by operating activities was $2.9 million for the six months ended July 4, 2009, a reversal from a $1.5 million usage in the prior year period.
Guidance, Outlook, and Risks
- Liquidity and Debt: The company maintains an asset-based revolving line of credit with Wells Fargo Bank up to $8.0 million. As of July 4, 2009, $4.5 million was outstanding with approximately $2.0 million in additional borrowing capacity. Management believes current cash and credit facilities are sufficient for the next 12 months, provided debt covenants are met.
- Legal Settlement: The company received an $800,000 payment from Synergetics related to a 2007 patent infringement settlement. Two payments of $800,000 remain to be received over the next two years.
- Subsequent Event: On July 30, 2009, the company filed a Tender Offer Statement to exchange certain existing employee stock options for new options priced at the closing price on the final day of the offer (scheduled for August 27, 2009).
- Risk Factors:
- Economic Sensitivity: Continued global economic slowdowns may further reduce demand for discretionary aesthetics procedures and capital equipment purchases.
- Debt Covenants: Failure to meet debt covenants could result in the bank declaring all obligations due and disposing of collateral.
- Patent Expiration: The "Connector Patent" protecting consumable EndoProbe devices is set to expire in the second half of 2010, potentially increasing competition.
- Internal Controls: While material weaknesses have been remediated, significant deficiencies remain regarding the accounting close process and inventory controls.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain the borrowing base (accounts receivable and inventory) required by the Wells Fargo credit facility amidst economic uncertainty.
- Aesthetics Segment Recovery: Monitor trends in the aesthetics segment to determine if the sharp revenue decline is a temporary economic effect or a structural shift in demand.
- Recurring Revenue Stability: Assess the stability of ophthalmology recurring revenues (consumables and service) as a buffer against capital equipment sales volatility.
- Patent Expiration Impact: Evaluate the potential impact of the 2010 Connector Patent expiration on the high-margin consumable business.
- Internal Control Remediation: Confirm progress on remedying significant deficiencies in internal controls over financial reporting to prevent future restatements or regulatory scrutiny.